Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer

Matti Annala(Tampere University), Alexander W. Wyatt(University of British Columbia), Kevin Beja(University of British Columbia), Eric J. Small(CancerCare Manitoba), Alan So(University of British Columbia), Irma-Liisa Seppälä(Tampere University), Daniel Khalaf(BC Cancer Agency), Gillian Vandekerkhove(University of British Columbia), Martin Gleave(University of British Columbia), Gregory Lo(Regional Municipality of Durham), Matti Nykter(University of Liverpool), Werner J. Struss(University of British Columbia), Rahul Aggarwal(UCSF Helen Diller Family Comprehensive Cancer Center), Amanda Wong(University of British Columbia), Evan W. Warner(Guardant (United States)), Kim N.(Asian Institute of Technology)
European Urology
March 2, 2017
10.1016/j.eururo.2017.02.023
Cited by 218

Related Papers

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k